Kyverna TherapeuticsKYTX
KYTX
About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Employees: 119
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
1% less funds holding
Funds holding: 88 [Q4 2024] → 87 (-1) [Q1 2025]
7.16% less ownership
Funds ownership: 66.88% [Q4 2024] → 59.71% (-7.16%) [Q1 2025]
54% less capital invested
Capital invested by funds: $108M [Q4 2024] → $50M (-$58.1M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
55%
upside
Avg. target
$12.50
288%
upside
High target
$20
521%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor | 55%upside $5 | Buy Upgraded | 27 May 2025 |
Morgan Stanley Michael Ulz | 521%upside $20 | Overweight Maintained | 1 Apr 2025 |
Financial journalist opinion
Based on 3 articles about KYTX published over the past 30 days
Neutral
PRNewsWire
2 weeks ago
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 4, 2025, at 4:55 p.m.
Positive
Benzinga
2 weeks ago
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025.
Neutral
GlobeNewsWire
1 month ago
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our investigation concerns whether the board of directors of Kyverna have breached their fiduciary duties to the company.
Neutral
PRNewsWire
1 month ago
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025 Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise Strong financial position; cash runway into 2027 supports first BLA filing, MG Phase 3 trial and pre-launch activities EMERYVILLE, Calif. , May 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended March 31, 2025.
Neutral
PRNewsWire
2 months ago
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026 Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025 Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts EMERYVILLE, Calif. , March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024.
Positive
Seeking Alpha
2 months ago
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026.
Neutral
PRNewsWire
3 months ago
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
EMERYVILLE, Calif. , March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m.
Positive
Zacks Investment Research
4 months ago
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Accesswire
4 months ago
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=128046&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
4 months ago
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.
Charts implemented using Lightweight Charts™